AJANTA PHARMA Financial Statement Analysis
|
||
|
The Revenues of AJANTA PHARMA have increased by 10.44% YoY .
The Earnings Per Share (EPS) of AJANTA PHARMA has increased by 14.74 % YoY. |
||
AJANTA PHARMA Last 5 Annual Financial Results
[BOM: 532331|NSE : AJANTPHARM]
| Consolidated | Mar2026 | Mar2025 | Mar2024 | Mar2023 | Mar2022 |
|---|---|---|---|---|---|
| Revenues | ₹4,648 Cr | ₹4,209 Cr | ₹3,743 Cr | ₹3,341 Cr | ₹2,890 Cr |
| Expenses | ₹3,389 Cr | ₹3,037 Cr | ₹2,959 Cr | ₹2,412 Cr | ₹1,891 Cr |
| Operating Profit (Excl OI) | ₹1,260 Cr | ₹1,172 Cr | ₹783 Cr | ₹929 Cr | ₹999 Cr |
| Other Income | ₹95 Cr | ₹85 Cr | ₹99 Cr | ₹116 Cr | ₹26 Cr |
| Interest | ₹21 Cr | ₹7.21 Cr | ₹5.84 Cr | ₹10 Cr | ₹8.27 Cr |
| Depreciation | ₹144 Cr | ₹135 Cr | ₹131 Cr | ₹125 Cr | ₹116 Cr |
| Profit Before Tax | ₹1,189 Cr | ₹1,114 Cr | ₹745 Cr | ₹909 Cr | ₹900 Cr |
| Profit After Tax | ₹920 Cr | ₹816 Cr | ₹588 Cr | ₹713 Cr | ₹654 Cr |
| Consolidated Net Profit | ₹920 Cr | ₹816 Cr | ₹588 Cr | ₹713 Cr | ₹654 Cr |
| Earnings Per Share (Rs) | ₹84.55 | ₹73.69 | ₹64.83 | ₹46.70 | ₹83.45 |
| PAT Margin (%) | 9.35 | 10.34 | 10.23 | 8.20 | 20.99 |
| ROE(%) | 25.42 | 25.06 | 23.49 | 17.68 | 22.77 |
| ROCE(%) | 32.67 | 32.87 | 32.22 | 22.57 | 29.37 |
| Total Debt/Equity(x) | 0.05 | 0.00 | 0.00 | 0.00 | 0.00 |
Key Financials |
||
| Market Cap | : | ₹ 38,252.5 Cr |
| Revenue (TTM) | : | ₹ 5,452.9 Cr |
| Net Profit(TTM) | : | ₹ 1,056.0 Cr |
| EPS (TTM) | : | ₹ 84.5 |
| P/E (TTM) | : | 36.2 |
| Industry Peers & Returns | 1W | 1M | 1Y |
| AJANTA PHARMA | 0.1% | -4% | 16.7% |
| SUN PHARMACEUTICAL INDUSTRIES | 1.7% | -2.3% | 8% |
| DIVIS LABORATORIES | 2% | -2.2% | 1.5% |
| TORRENT PHARMACEUTICALS | -1.8% | -0.1% | 36.7% |
| CIPLA | -2% | -3.3% | -9.9% |
| DR REDDYS LABORATORIES | -0.6% | -3.8% | -6.9% |
| MANKIND PHARMA | 1.5% | -6.4% | 1% |
| LUPIN | 3.5% | 3% | 16.4% |
| ZYDUS LIFESCIENCES | -1.6% | 2.9% | 10.2% |
AJANTA PHARMA Revenues
[BOM: 532331|NSE : AJANTPHARM]
| Y-o-Y | 10.44 % |
| 5 Yr CAGR | 12.62 % |
| Years | Revenues | % Change | |
|---|---|---|---|
| Mar2026 | ₹4,648 Cr | 10.44 | |
| Mar2025 | ₹4,209 Cr | 12.45 | |
| Mar2024 | ₹3,743 Cr | 12.02 | |
| Mar2023 | ₹3,341 Cr | 15.62 | |
| Mar2022 | ₹2,890 Cr | - | |
AJANTA PHARMA Operating Profit
[BOM: 532331|NSE : AJANTPHARM]
| Y-o-Y | 7.47 % |
| 5 Yr CAGR | 5.98 % |
| Years | Operating Profit | % Change | |
|---|---|---|---|
| Mar2026 | ₹1,260 Cr | 7.47 | |
| Mar2025 | ₹1,172 Cr | 49.63 | |
| Mar2024 | ₹783 Cr | -15.72 | |
| Mar2023 | ₹929 Cr | -6.94 | |
| Mar2022 | ₹999 Cr | - | |
| Operating Margins | |
|---|---|
| Y-o-Y | -2.69 % |
| 5 Yr CAGR | -5.90 % |
| Years | Operating Margin% | % Change | |
|---|---|---|---|
| Mar2026 | 27.1% | -2.69 | |
| Mar2025 | 27.85% | 33.06 | |
| Mar2024 | 20.93% | -24.74 | |
| Mar2023 | 27.81% | -19.53 | |
| Mar2022 | 34.56% | - | |
AJANTA PHARMA Profit After Tax
[BOM: 532331|NSE : AJANTPHARM]
| Y-o-Y | 12.77 % |
| 5 Yr CAGR | 8.92 % |
| Years | Profit After Tax | % Change | |
|---|---|---|---|
| Mar2026 | ₹920 Cr | 12.77 | |
| Mar2025 | ₹816 Cr | 38.81 | |
| Mar2024 | ₹588 Cr | -17.50 | |
| Mar2023 | ₹713 Cr | 8.99 | |
| Mar2022 | ₹654 Cr | - | |
| PAT Margins | |
|---|---|
| Y-o-Y | -9.57 % |
| 5 Yr CAGR | -18.30 % |
| Years | PAT Margin(%) | % Change | |
|---|---|---|---|
| Mar2026 | 9.35 % | -9.57 | |
| Mar2025 | 10.34 % | 1.08 | |
| Mar2024 | 10.23 % | 24.76 | |
| Mar2023 | 8.2 % | -60.93 | |
| Mar2022 | 20.99 % | - | |
AJANTA PHARMA Earnings Per Share (EPS)
[BOM: 532331|NSE : AJANTPHARM]
| Y-o-Y | 14.74 % |
| 5 Yr CAGR | 0.33 % |
| Years | EPS | % Change | |
|---|---|---|---|
| Mar2026 | ₹85 | 14.74 | |
| Mar2025 | ₹74 | 13.67 | |
| Mar2024 | ₹65 | 38.82 | |
| Mar2023 | ₹47 | -44.04 | |
| Mar2022 | ₹83 | - | |
AJANTA PHARMA Return on Capital Employed (ROCE)
[BOM: 532331|NSE : AJANTPHARM]
| Y-o-Y | -0.61 % |
| 5 Yr CAGR | 2.70 % |
| Years | ROCE | % Change | |
|---|---|---|---|
| Mar2026 | 32.67% | -0.61 | |
| Mar2025 | 32.87% | 2.02 | |
| Mar2024 | 32.22% | 42.76 | |
| Mar2023 | 22.57% | -23.15 | |
| Mar2022 | 29.37% | - | |
AJANTA PHARMA Share Price vs Sensex
| Current Share Price | : | ₹3,062.7 |
| Current MarketCap | : | ₹ 38,252.5 Cr |
| Updated EOD on | : | Jun 19,2026 |
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| AJANTA PHARMA | 0.1% |
-4% |
16.7% |
| SENSEX | 1.7% |
2.1% |
-6% |
AJANTA PHARMA related INDICES
| BSE Indices | 1W | 1M | 1Y |
|---|---|---|---|
| BSE 400 MIDSMALLCAP INDEX | 3.4% | 4.1% | 4% |
| BSE 150 MIDCAP INDEX | 3.3% | 3.1% | 5% |
| BSE 1000 | 2.5% | 3.2% | 0.4% |
| BSE 500 | 2.4% | 2.8% | 0.1% |
| BSE 250 LARGEMIDCAP INDEX | 2.2% | 2.4% | -0.3% |
| NSE Indices | 1W | 1M | 1Y |
|---|---|---|---|
| NIFTY MIDCAP150 QUALITY 50 | 3.5% | 3.8% | -0.9% |
| NIFTY MIDSMALLCAP400 50:50 | 3.5% | 4.5% | NA |
| NIFTY 500 EQUAL WEIGHT | 3.4% | 4.8% | 3.1% |
| NIFTY MIDSMALLCAP 400 | 3.4% | 3.9% | 5.2% |
| NIFTY MIDCAP 150 | 3.2% | 2.7% | 6.8% |
You may also like the below Video Courses
FAQ about AJANTA PHARMA Financials
How the annual revenues of AJANTA PHARMA have changed ?
The Revenues of AJANTA PHARMA have increased by 10.44% YoY .
How the Earnings per Share (EPS) of AJANTA PHARMA have changed?
The Earnings Per Share (EPS) of AJANTA PHARMA has increased by 14.74 % YoY .
SUN PHARMACEUTICAL INDUSTRIES LTD vs DIVIS LABORATORIES LTD vs TORRENT PHARMACEUTICALS LTD
CIPLA LTD vs DR REDDYS LABORATORIES LTD vs